Reports Q4 revenue $28.4M, consensus $27.53M. Will Febbo, OptimizeRx CEO commented, “Q4 of 2023 ended strongly, setting the Company up well for 2024. Our revenue for the quarter exceeded expectations, reaching $28.4 million, a 44% increase year-over-year. This was fueled by organic growth through our Dynamic Audience Activation Platform and a two-month contribution from the Medicx Health acquisition. Notably, our core HCP business saw an over 30% growth compared to Q4 2022.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPRX:
- OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
- OptimizeRx’s preliminary Q4 results support bullish thesis, says Roth MKM
- OptimizeRx initiated with an Outperform at JMP Securities
- OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
- OptimizeRx cuts FY24 revenue view to at least $100M from at least $110M
